WO2001041766A1 - The combination of a serotonin reuptake inhibitor and irindalone - Google Patents

The combination of a serotonin reuptake inhibitor and irindalone Download PDF

Info

Publication number
WO2001041766A1
WO2001041766A1 PCT/DK2000/000667 DK0000667W WO0141766A1 WO 2001041766 A1 WO2001041766 A1 WO 2001041766A1 DK 0000667 W DK0000667 W DK 0000667W WO 0141766 A1 WO0141766 A1 WO 0141766A1
Authority
WO
WIPO (PCT)
Prior art keywords
reuptake inhibitor
serotonin reuptake
serotonin
irindalone
pharmaceutical composition
Prior art date
Application number
PCT/DK2000/000667
Other languages
French (fr)
Inventor
Klaus Peter Bøgesø
Thomas Ivo Franciscus Hubert Cremers
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Priority to AU18508/01A priority Critical patent/AU1850801A/en
Publication of WO2001041766A1 publication Critical patent/WO2001041766A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9413—Dopamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Definitions

  • the present invention relates to the use of a combination of irindalone and a serotonin reuptake inhibitor (SRI), or any other compound, which causes an elevation in the level • ⁇ of extracellular serotonin, for the treatment of depression and other affective disorders
  • SRI serotonin reuptake inhibitor
  • SSRIs Selectn e serotonin reuptake inhibitors
  • Augmentation of antidepressant therapy may be accomplished through the co- admimstration of mood stabilizers such as lithium carbonate or t ⁇ iodothyronin or by the use of electroshock
  • the present invention 1 elates to the use of irindalone or a pharmaceutically acceptable 0 salt thereof for the preparation of a pharmaceutical composition to be used m combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extiacellular serotonin
  • the present invention relates to the use of irindalone or a pharmaceutically s acceptable salt thereof for the preparation of a pharmaceutical composition useful foi augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation m the level of extracellulai serotonin
  • the present invention relates to the use as above, of irindalone, or a pharmaceutically acceptable salt thereof, for the treatment of depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder and drug abuse, in particular depression with a serotonin reuptake inhibitor or any other compound, which causes an elevation m the level of extracellular serotonin
  • the anxiety disorders mentioned above include general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder
  • augmenting covers improving the therapeutic effect and/oi potentiating the therapeutic effect of an SRI or a compound which causes an elevation in the level of extracellulai 5-HT
  • the invention relates to the use of irindalone or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or a compound, which causes an elevation m the level of extracellular serotonin, for the preparation of a pharmaceutical composition or kit for the treatment of diseases oi disorders responsive to the therapeutic effect of a serotonin reuptake inhibitoi, or any othei compound, which causes an elevation in the level of extiacellulai serotonin
  • the diseases responsive to a serotonin leuptake inhibitor include depression, anxiety disordeis and other affective disorders, eating disoideis such as bulimia, anorexia and obesity, phobias, dysthymia, premenstiual syndiome, cognitive disordei s, impulse contiol disordei s, attention deficit hypeiactivity disorder and drug abuse, in particular depi ession
  • anxiety disorders is as defined above.
  • the present invention relates to the use of irindalone oi a pharmaceutically acceptable salt thereof foi the preparation of a pharmaceutical composition as above, which is adapted for simultaneous administration of the actn e ingredients
  • such pharmaceutical compositions may contain the active ingredients within the same unit dosage form, e g in the same tablet or capsule
  • Such unit dosage forms may contain the active ingiedients as a homogenous mixture or in separate compartments of the unit dosage form
  • the present invention relates to the use of irindalone or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition or kit as above, which is adapted for sequential administration of the active ingredients
  • such pharmaceutical compositions may contain the active ingredients in discrete unit dosage forms, e g discrete tablets or capsules containing either of the active ingredients These discrete unit dosage forms may be contained in the same container or package, e g a blister pack
  • kit means a pharmaceutical composition containing each of the active ingredients, but in discrete unit dosage forms
  • the invention also relates to a pharmaceutical composition or kit comprising irindalone or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound, which causes an elevation m extracellular 5- HT, and optionally pharmaceutically acceptable carriers or diluents
  • composition or kit of the invention may be adapted for simultaneous administration of the active ingredients or for sequential administration of the active ingredients, as described above
  • the present invention relates to a method for the treatment of diseases oi disorders responsive to a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin, comprising administering irindalone or a pharmaceutically acceptable salt thereof and a serotonin reuptake inhibitor, or a compound, which causes an elevation in the level extracellular serotonin, to an individual in need thereof
  • the present invention relates to a method for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation m the level extracellular serotonin, comprising administering irindalone or a pharmaceutically acceptable salt thereof to an individual to be treated with or undergoing treatment with the serotonin reuptake inhibitor or any othei compound, which causes an elevation m the level of extracellular serotonin
  • the individuals which may benefit from treatment with a combination as above, may suffer from depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, premenstrual syndrome, dysthymia, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder and drug abuse, in particular depression.
  • anxiety disorder includes general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder.
  • Irindalone and the serotonin reuptake inhibitor may be administered simultaneously as described above.
  • the active ingredients may be administered sequentially, e.g. in two discrete unit dosage forms as described above.
  • EP-Bl-183 349 are covered by EP-Bl-183 349.
  • the compounds claimed therein are described as being useful for the treatment of hypertension and other cardiovascular diseases as well as anxiety.
  • Irindalone has also been described as a potent peripheral 5-HT 2 antagonist with no or only low affinity for 5-HT I A and 5-HT ⁇ B receptors (Hyttel et al., Drug Dev. Res. 1988b, 15, 389-404, Arnt et al., Drug Dev Res. 1989, 16, 59-70 and B ⁇ ges ⁇ et al , Schizophrenia, Alfred Benzon Symposium 38, 1995, p 361-374)
  • serotonin reuptake inhibitors show delayed onset of action Even m responders to SSRIs, several weeks of treatment are necessary to achieve a relief in symptoms Animal studies have shown that irindalone may provide fast onset of therapeutic effect of serotonin reuptake inhibitors
  • irindalone may be used as add-on therapy for the augmentation of the response to SRIs in patients where at least 40-60% reduction m symptoms has not been achieved du ⁇ ng the first 6 weeks of treatment with an SRI
  • the following list contains a number of serotonin reuptake inhibitors, which may benefit from augmentation with irindalone citalopram, escitalopram, fluoxetme, R-fluoxetme, sertralme, paroxetme, fluvoxamme, venlafaxine, duloxetine, dapoxetme, nefazodone, lmipramme, lmipramme N-oxide, desipramme, pirandamme, dazepinil, nefopam, befuralme, fezolamine, femoxetme, clomipramme, cianoimipramine, htoxetine, ce ⁇ clamme, seproxetme, WY 27587, WY 27866, lmeldine, ifoxetme, tiflucarbme, viqua ne, milnacipran, apelinap ⁇ ne, Y
  • Othei therapeutic compounds which may benefit from augmentation with irindalone, include compounds, which causes an elevation in the extracellular level of 5-HT in the synaptic cleft, although they are not serotonin leuptake inhibitors
  • One such compound is tianeptine
  • seiotonm reuptake inhibitois and other compounds which causes an increase in the extracellulai level of serotonin, may not be construed as limiting
  • SRIs which aie particularly preferred according to the present invention, include citalopram. escitalopram, fluoxetme, sertralme, paroxetme, fluvoxamme. venlafaxine, dapoxetme. nefazodone, lmipramin, femoxetme and clomipramme
  • SSRI selective serotonin reuptake mhibitoi
  • SSRIs selective serotonin reuptake inhibitors
  • Particularly preferred SSRIs according to the invention are citalopram, escitalopram, fluoxetme, fluvoxamme, sertralme or paroxetme
  • the active ingredients according to the invention may be used in the free base form or in the form of a pharmaceutically acceptable acid addition salt thereof, the lattei being obtainable by reaction of the base form with an appropriate acid
  • Citalopram is preferably used in the form of the hydrobromide or as the base, escitalopram m the form of the oxalate, fluoxetme, sertralme and paroxetme in the form of the hydrochlo ⁇ de and fluvoxamme in the form of the maleate
  • Irindalone is preferably used m the form of the tartrate salt
  • the combination of irindalone with a serotonin reuptake inhibitor unexpectedly shows a synergistic effect on the central nervous system (CNS)
  • CNS central nervous system
  • combination therapy with irindalone using a normal dose of serotonin reuptake inhibitor has the advantage that an effective CNS effect may be obtained in the often large number of patients who do not respond to conventional monotherapy with SSRIs
  • the amount of irindalone used in combination therapy may range from about 0 1 to about 150 mg/day, particulaily from about 0 1 to about 100 mg/day and more particularly from about 0 5 to about 50 mg/day and even more particularly from about 1 to about 5 mg/day
  • Serotonin reuptake inhibitors including the SSRIs specifically mentioned heremabove, differ both in molecular weight and in activity
  • the amount of serotonin reuptake inhibitor used m combination therapy depends on the nature of said serotonin reuptake inhibitor
  • the serotonin reuptake inhibitor or the compound causing an increase m the level of extracellular 5-HT is administered at lower doses than required when the compound is used alone
  • the serotonin reuptake inhibitor or the compound causing an increase in the level of extracellular 5-HT is administered in normal doses
  • compositions of this invention an appropriate amount of the active mgred ⁇ ent(s), in salt form or base form, is combined in an intimate admixture with a pharmaceutically acceptable carrier, which can take a wide variety of forms depending on the form of preparation desired for administration
  • a pharmaceutically acceptable carrier which can take a wide variety of forms depending on the form of preparation desired for administration
  • these pharmaceutical compositions are desirably in unitary dosage form suitable for administration orally, rectally, percutaneously or by parenteral injection
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carrieis such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, m which case solid pharmaceutical carriers are obviously employed
  • unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active mgred ⁇ ent(s) calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier
  • dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, mjectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
  • Irindalone may be administered before, during or after the administration of the serotonin reuptake inhibitor provided that the time between the administration of irindalone and the administration of the serotonin reuptake inhibitor is such that ingredients are allowed to act syneigistically on the CNS
  • a composition containing both a serotonin reuptake inhibitor and irindalone may be particularly convenient
  • irindalone and the serotonin reuptake inhibitor may be administered separately in the form of suitable compositions
  • the compositions may be prepared as described heremabove
  • the present invention also comprises products containing irindalone and a serotonin reuptake inhibitor as a combination preparation for simultaneous, separate or sequential use in psychiatnc drug therapy
  • Such products may comprise, for example, a kit compnsing discrete unit dosage forms containing irindalone and discrete unit dosage forms containing a serotonin reuptake inhibitor, all contained in the same container or l*> pack, e g a blister pack
  • preparations for simultaneous or sequential administration may instead of a serotonin reuptake inhibitor contain another compound causing an elevation in the level of extracellular 5-HT 0
  • mice Male Sprague-Dawley rats, initially weighing 250 - 300 g, were used The animals weie housed under a 12-hr hght/daik cycle under controlled conditions for regulai m-dooi temperatuie (21 ⁇ 2°C) and humidity (55 ⁇ 5%) with food and tap water available ad 0 libitum
  • osmotic mini pumps Alzet, 2ML2 and 2ML4 (Alza Corporation, Palo Alto, USA) were used The pumps were filled under aseptic conditions and implanted subcutanously under Sevorane anaesthesia (Abbott Laboratories, Chicago, USA) Single injections:
  • Paroxetme and irindalone were injected alone or contemporary in doses of 5 mg/kg and 1 mg/kg s.c, respectively.
  • a microdialysis probe (CMA/12. 0 5 mm diameter, 3 mm length) was inserted through the guide cannula Perfusion of the microdialysis probe with filtered Ringer solution (145 mM NaCl, 3 mM KC1, 1 mM MgCl 2 , 1 2 mM CaCl 2 ) was begun shortly before insertion of the probe into the bram and continued for the duration of the expe ⁇ ment at constant flow of 1 ⁇ l/mm After the expenments, the rats were sac ⁇ ficed by decapitation, their brains frozen and sliced (20 ⁇ m) and the position of the probes was verified Analysis of dialysate 5-HT
  • Rats Male, wistar WU from M ⁇ llegard, Denmark were maintained on a food restricted diet and maintained at 85-90% of their free feeding weight for at least 7 days prior to the start of testing. Animals were trained (4-5 times per week) in an operant chamber on a fixed schedule (1 pellet every 30s) for 30 minutes per session. Drinking water was freely available, water intake was measured for every trial session Following three weeks of training water intake was stable (approximately 12 mL/rat/30 mm) and the animals were randomly allocated to treatment groups
  • the SRIs fluvoxamme, clomipramme and fluoxetme have all been demonstrated to reduce the intake of water the schedule induce polydipsia model.
  • the onset of action of the SSRIs alone is seen after 1-3 weeks, mirroring the clinical situation
  • the effect of the combination of paroxetine and irindalone is observed after one day's treatment suggesting that this combination would have a fast onset of effect in the clinic
  • the two-compartment test box is described by Sanchez et al Pharmacology & Toxicology 1995, 77, 71-78
  • the test box is open-topped and divided into one black and one white compartment (ratio 2 3) by a partition which is black on the side facing the black compartment and white on the side facing the white compartment
  • the white chamber is made of white perspex except for the lowest 7 5 cm
  • This part is made of transparent perspex (outer walls) and black perspex (partition)
  • the floor of the white compartment is divided into 9 fields and the compartment is illuminated by means of a Schott KL 1500 electronic lamp emitting cold light (560 Lux)
  • the black box is made of black perspex and the floor of this compartment is divided into 6 fields
  • the opening m the partition between the two compartments measures 7,5 x 7,5 cm
  • the black and white boxes aie placed in a dark room
  • the mice were transported to the animal holding room adjacent to the test room 18 hours before the test
  • the test was performed as follows the mouse was placed into the centie of the b ⁇ ghtly- lit white compartment facing the opening to the black compartment and allowed to freely explore the apparatus for a total of 5 mm
  • the light beams weie used to assess activity around the test box and critically the time for which the animals exploied the light and daik sections thereof
  • mice were randomly assigned to the following groups (8 mice per group)
  • mice in group 1 spent an average of 127 s (from a maximum of 300 s) in the light section of the box. Treatment with paroxetine (group 2) increased this to 143 s which is not significant. Animals treated with irindalone alone (groups 3 and 4) had average times in light of 140 and 148 s for 0.31 and 1.3 mg/kg doses, respectively; which is not significant. The mice treated with the combination of paroxetine and irindalone spent an average of 162 s (group 5) and 174 s (group 6) in the light. Group 5 was significantly different from group 1 (P ⁇ 0.05) whilst group 6 was significantly different from group 1 , group 2 and group 4 (P ⁇ 0.05).
  • mice treated with the two vehicles had an average time in light of 123 + 16 s.
  • Treatment with paroxetine did not significantly change the level of exploration in light (group 2, 132 + 10 s; group 3, 140 + 12 s; group 4, 157 + 10 s; not significant).
  • irindalone alone (group 5) was without effect (average time in light 142 + 20 s; not significant).
  • the animals treated with the combination of paroxetine and irindalone have the following average times in light; group 6, 143 + 1 1 s; group 7, 203 + 22 s (PO.05 vs groups 1 and 3) and group 8, 206 + 10 s (P ⁇ 0.05 vs groups 1, 4 and 5).
  • irindalone potentiated the anxiolytic potential of paroxetine suggesting better efficacy for the combination treatment than the paroxetine alone.
  • the benefit was observed following acute and importantly chronic treatment with paroxetine suggesting the potential of irindalone as an "add-on" therapy to enhance the efficacy of SSRIs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)

Abstract

The present invention relates to the use of a combination of irindalone and a serotonin reuptake inhibitor (SRIs), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.

Description

The combination of a serotonin reuptake inhibitor and Irindalone
The present invention relates to the use of a combination of irindalone and a serotonin reuptake inhibitor (SRI), or any other compound, which causes an elevation in the level •^ of extracellular serotonin, for the treatment of depression and other affective disorders
Background
Selectn e serotonin reuptake inhibitors (hereinafter referred to as SSRIs) have become 10 first choice therapeutics in the treatment of depression, certain forms of anxiety and social phobias, because they are effective, w ell tolerated and have a favourable safety profile compared to the classic tncvclic antidepressants
Howevei, clinical studies on depression and anxiety disorders indicate that non-response i s to SSRIs is substantial, up to 30% Another, often neglected, factor in antidepressant treatment is compliance, which has a rather profound effect on the patient s motivation to continue pharmacotherapy
First of all, there is the delay in therapeutic effect of SSRIs Sometimes symptoms even 20 woisen during the first weeks of treatment Secondly, sexual dysfunction is a side effect common to all SSRIs Without addressing these problems, real progress m the pharmacotherapv of depression and anxiety disorders is not hkelv to happen
In order to cope with non-response, psvchiatπsts sometimes make use of augmentation 2 strategies Augmentation of antidepressant therapy may be accomplished through the co- admimstration of mood stabilizers such as lithium carbonate or tπiodothyronin or by the use of electroshock
In 1993. an augmentation strategy with pindolol was described by Artigas et al in Tiends ^0 Pharmacol Sci 1993 14, p 262-263 Artigas' idea is based on mtracerebral microdialysis experiments m animals In fact, later neurochemical studies built on the desensitization hypothesis by B er and co-workers stated that the delay in therapeutic effect of antidepressants is related to a gradual desensitization of 5-HT autoreceptors (Blier et al J Clin Psycψharmacol 1987, 7 suppl 6, 24S-35S) A key point in their hypothesis is that the effects of SSRIs on the release-controlling somatodendπtic autoreceptors (5-HTI A) limit the release of 5-HT in terminal areas and thus the effect of 5- HT uptake inhibition m those regions This is supported by microdialysis expeπments in rats, showing that the increase in extracellular 5-HT elicited by a single dose of an SSRI is augmented by co-admmistration of a 5-HTιA autoreceptor antagonist (Invernizzi et al Brain Res 1992, 584, p 322-324 and Hjorth, S , J Neurochem, 1993, 60, p 776-779)
The effect of combined administration of a compound that inhibits serotonin reuptake and a 5-HT i A leceptor antagonist has been evaluated in several studies (Innis, R B et al Ew J Pharmacol 1987 143, p 1095-204 and Gartside, S E , Br J Pharmacol, 1995, 115, p 1064-1070, Bhei, P et al Trends in Pharmacol Science 1994, 15, 220) In these studies it was found that 5-HTι \ receptor antagonists would abolish the initial brake on 5-HT neurotransmission induced by the serotonin reuptake inhibitors and thus produce an immediate boost of 5-HT transmission and a rapid onset of therapeutic action
Seveial patent applications have been filed which cover the use of a combination of a 5- HT I A antagonist and a serotonin reuptake inhibitor for the treatment of depression (see e g EP-A2-687 472 and EP-A2-714 663)
Anothei approach to increase terminal 5-HT would be through blockade of the 5-HT] H autoreceptor Microdialysis experiments in rats have indeed shown that increase of hippocampal 5-HT by citalopram is potentiated by GMC 2-29, an experimental 5-HTI B receptor antagonist Several patent applications covering the combination of an SSRI and a 5-HT]B antagonist or partial agonist have also been filed (WO 97/28141 , WO 96/03400, EP-A-701819 and WO 99/13877)
It has now surprisingly been found that irindalone having the general formula
Figure imgf000004_0001
or pharmaceutically acceptable salts thereof may be used to augment and provide faster onset of the therapeutic effect of serotonin reuptake inhibitors
ι The invention
The piesent invention thus provides
The present invention 1 elates to the use of irindalone or a pharmaceutically acceptable 0 salt thereof for the preparation of a pharmaceutical composition to be used m combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extiacellular serotonin
In particular the present invention relates to the use of irindalone or a pharmaceutically s acceptable salt thereof for the preparation of a pharmaceutical composition useful foi augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation m the level of extracellulai serotonin
0 More particularly, the present invention relates to the use as above, of irindalone, or a pharmaceutically acceptable salt thereof, for the treatment of depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder and drug abuse, in particular depression with a serotonin reuptake inhibitor or any other compound, which causes an elevation m the level of extracellular serotonin
The anxiety disorders mentioned above include general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder
As used herein, the term augmenting covers improving the therapeutic effect and/oi potentiating the therapeutic effect of an SRI or a compound which causes an elevation in the level of extracellulai 5-HT
In a furthei embodiment, the invention relates to the use of irindalone or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or a compound, which causes an elevation m the level of extracellular serotonin, for the preparation of a pharmaceutical composition or kit for the treatment of diseases oi disorders responsive to the therapeutic effect of a serotonin reuptake inhibitoi, or any othei compound, which causes an elevation in the level of extiacellulai serotonin
The diseases responsive to a serotonin leuptake inhibitor include depression, anxiety disordeis and other affective disorders, eating disoideis such as bulimia, anorexia and obesity, phobias, dysthymia, premenstiual syndiome, cognitive disordei s, impulse contiol disordei s, attention deficit hypeiactivity disorder and drug abuse, in particular depi ession
The term anxiety disorders is as defined above
In one embodiment, the present invention relates to the use of irindalone oi a pharmaceutically acceptable salt thereof foi the preparation of a pharmaceutical composition as above, which is adapted for simultaneous administration of the actn e ingredients In particular, such pharmaceutical compositions may contain the active ingredients within the same unit dosage form, e g in the same tablet or capsule Such unit dosage forms may contain the active ingiedients as a homogenous mixture or in separate compartments of the unit dosage form In another embodiment, the present invention relates to the use of irindalone or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition or kit as above, which is adapted for sequential administration of the active ingredients In particular, such pharmaceutical compositions may contain the active ingredients in discrete unit dosage forms, e g discrete tablets or capsules containing either of the active ingredients These discrete unit dosage forms may be contained in the same container or package, e g a blister pack
As used herein the term kit means a pharmaceutical composition containing each of the active ingredients, but in discrete unit dosage forms
The invention also relates to a pharmaceutical composition or kit comprising irindalone or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound, which causes an elevation m extracellular 5- HT, and optionally pharmaceutically acceptable carriers or diluents
The pharmaceutical composition or kit of the invention may be adapted for simultaneous administration of the active ingredients or for sequential administration of the active ingredients, as described above
Finally, the present invention relates to a method for the treatment of diseases oi disorders responsive to a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin, comprising administering irindalone or a pharmaceutically acceptable salt thereof and a serotonin reuptake inhibitor, or a compound, which causes an elevation in the level extracellular serotonin, to an individual in need thereof
In particular, the present invention relates to a method for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation m the level extracellular serotonin, comprising administering irindalone or a pharmaceutically acceptable salt thereof to an individual to be treated with or undergoing treatment with the serotonin reuptake inhibitor or any othei compound, which causes an elevation m the level of extracellular serotonin The individuals, which may benefit from treatment with a combination as above, may suffer from depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, premenstrual syndrome, dysthymia, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder and drug abuse, in particular depression.
As mentioned above, anxiety disorder includes general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder.
Irindalone and the serotonin reuptake inhibitor may be administered simultaneously as described above.
Alternatively, the active ingredients may be administered sequentially, e.g. in two discrete unit dosage forms as described above.
Irindalone and pharmaceutically acceptable salts thereof having the general formula
Figure imgf000007_0001
are covered by EP-Bl-183 349. The compounds claimed therein are described as being useful for the treatment of hypertension and other cardiovascular diseases as well as anxiety.
Irindalone has also been described as a potent peripheral 5-HT2 antagonist with no or only low affinity for 5-HTI A and 5-HTι B receptors (Hyttel et al., Drug Dev. Res. 1988b, 15, 389-404, Arnt et al., Drug Dev Res. 1989, 16, 59-70 and Bøgesø et al , Schizophrenia, Alfred Benzon Symposium 38, 1995, p 361-374)
It has now, surprisingly, been found that co-administration of irindalone and a serotonin reuptake inhibitor produces a significant increase in the level of serotonin in terminal areas, as measured in microdialysis experiments, compared to the administration of the serotonin reuptake inhibitor alone Administration of irindalone alone causes no increase in serotonin levels as measured in microdialysis experiments
As mentioned above, serotonin reuptake inhibitors show delayed onset of action Even m responders to SSRIs, several weeks of treatment are necessary to achieve a relief in symptoms Animal studies have shown that irindalone may provide fast onset of therapeutic effect of serotonin reuptake inhibitors
It has also been found that irindalone potentiates the anxiolytic potential of serotonin reuptake inhibitors.
The use of a combination of irindalone and a serotonin reuptake inhibitor may greatly reduce the amount of serotonin reuptake inhibitor necessary to treat depression and othei affective disordeis and may thus reduce the side effects caused by the serotonin reuptake nihibitoi In particular the combination of a reduced amount of SRI and irindalone may reduce the risk of SSRI-mduced sexual dysfunction and sleep disturbances
Co-administration of irindalone and a serotonin reuptake inhibitor may also be useful for the treatment of refractory depression, l e depression, which cannot be treated appropπately by administration of a serotonin reuptake inhibitor alone Typically, irindalone may be used as add-on therapy for the augmentation of the response to SRIs in patients where at least 40-60% reduction m symptoms has not been achieved duπng the first 6 weeks of treatment with an SRI
Many antidepressants with serotonin reuptake inhibiting effect have been described in the literature Any pharmacologically active compound, which primarily or partly exert its therapeutic effect via inhibition of serotonin reuptake in the CNS, may benefit from augmentation with irindalone
The following list contains a number of serotonin reuptake inhibitors, which may benefit from augmentation with irindalone citalopram, escitalopram, fluoxetme, R-fluoxetme, sertralme, paroxetme, fluvoxamme, venlafaxine, duloxetine, dapoxetme, nefazodone, lmipramme, lmipramme N-oxide, desipramme, pirandamme, dazepinil, nefopam, befuralme, fezolamine, femoxetme, clomipramme, cianoimipramine, htoxetine, ceπclamme, seproxetme, WY 27587, WY 27866, lmeldine, ifoxetme, tiflucarbme, viqua ne, milnacipran, bazinapπne, YM 922, S 33005, F 98214-TA, OPC 14523, alaproclate, cyanodothepme, tπmipramme, qumupramine, dothiepin, amoxapme, nitioxazepme, McN 5652, McN 5707, 01 77, Oig 6582, Org 6997, Org 6906, amitπptyhne, amitπptyhne N-oxide, nortπptyhne, CL 255 663, pnlindole, indatraline, LY 1 13 821, LY 214 281 , CGP 6085 A, RU 25 591, napamezole, diclofensme, tiazodone, EMD 68 843, BMY 42 569, NS 2389, sercloremine, mtroquipazine, ademethion e, sibutramine and clovoxamme The compounds mentioned above may be used m the form of the base or a pharmaceutically acceptable acid addition salt thereof
Othei therapeutic compounds, which may benefit from augmentation with irindalone, include compounds, which causes an elevation in the extracellular level of 5-HT in the synaptic cleft, although they are not serotonin leuptake inhibitors One such compound is tianeptine
The above list of seiotonm reuptake inhibitois and other compounds, which causes an increase in the extracellulai level of serotonin, may not be construed as limiting
SRIs, which aie particularly preferred according to the present invention, include citalopram. escitalopram, fluoxetme, sertralme, paroxetme, fluvoxamme. venlafaxine, dapoxetme. nefazodone, lmipramin, femoxetme and clomipramme
The term selective serotonin reuptake mhibitoi (SSRI) means an inhibitor of the monoamme transporters which has stronger inhibitory effect at the serotonin transportei than the dopam e and the noradrenalme transporters Selective serotonin reuptake inhibitors (SSRIs) are among the most preferred serotonin reuptake inhibitors used according to the present invention Particularly preferred SSRIs according to the invention are citalopram, escitalopram, fluoxetme, fluvoxamme, sertralme or paroxetme
The active ingredients according to the invention, l e irindalone and the SRI or a compound causing an increase in extracellular serotonin levels, may be used in the free base form or in the form of a pharmaceutically acceptable acid addition salt thereof, the lattei being obtainable by reaction of the base form with an appropriate acid
Citalopram is preferably used in the form of the hydrobromide or as the base, escitalopram m the form of the oxalate, fluoxetme, sertralme and paroxetme in the form of the hydrochloπde and fluvoxamme in the form of the maleate
Irindalone is preferably used m the form of the tartrate salt
As mentioned above, the combination of irindalone with a serotonin reuptake inhibitor unexpectedly shows a synergistic effect on the central nervous system (CNS) As a consequence, combination therapy using irindalone and lower doses of the serotonin reuptake inhibitor than normally used in monotherapy, may be effective, and side-effects associated with the larger amounts of serotonin reuptake inhibitor used in monotherapy may be reduced or prevented altogether
Additionally, combination therapy with irindalone using a normal dose of serotonin reuptake inhibitor has the advantage that an effective CNS effect may be obtained in the often large number of patients who do not respond to conventional monotherapy with SSRIs
The amount of irindalone used in combination therapy may range from about 0 1 to about 150 mg/day, particulaily from about 0 1 to about 100 mg/day and more particularly from about 0 5 to about 50 mg/day and even more particularly from about 1 to about 5 mg/day Serotonin reuptake inhibitors, including the SSRIs specifically mentioned heremabove, differ both in molecular weight and in activity As a consequence, the amount of serotonin reuptake inhibitor used m combination therapy depends on the nature of said serotonin reuptake inhibitor In one embodiment of the invention, the serotonin reuptake inhibitor or the compound causing an increase m the level of extracellular 5-HT, is administered at lower doses than required when the compound is used alone In anothei embodiment, the serotonin reuptake inhibitor or the compound causing an increase in the level of extracellular 5-HT, is administered in normal doses
To prepare the pharmaceutical compositions of this invention, an appropriate amount of the active mgredιent(s), in salt form or base form, is combined in an intimate admixture with a pharmaceutically acceptable carrier, which can take a wide variety of forms depending on the form of preparation desired for administration These pharmaceutical compositions are desirably in unitary dosage form suitable for administration orally, rectally, percutaneously or by parenteral injection For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carrieis such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, m which case solid pharmaceutical carriers are obviously employed
It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage As used in the specification and claims, unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active mgredιent(s) calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, mjectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof. Irindalone may be administered before, during or after the administration of the serotonin reuptake inhibitor provided that the time between the administration of irindalone and the administration of the serotonin reuptake inhibitor is such that ingredients are allowed to act syneigistically on the CNS When simultaneous administration of irindalone and a ι seiotonin reuptake inhibitor is envisaged, a composition containing both a serotonin reuptake inhibitor and irindalone may be particularly convenient Or, irindalone and the serotonin reuptake inhibitor may be administered separately in the form of suitable compositions The compositions may be prepared as described heremabove
10 The present invention also comprises products containing irindalone and a serotonin reuptake inhibitor as a combination preparation for simultaneous, separate or sequential use in psychiatnc drug therapy Such products may comprise, for example, a kit compnsing discrete unit dosage forms containing irindalone and discrete unit dosage forms containing a serotonin reuptake inhibitor, all contained in the same container or l*> pack, e g a blister pack
The above mentioned preparations for simultaneous or sequential administration may instead of a serotonin reuptake inhibitor contain another compound causing an elevation in the level of extracellular 5-HT 0
Experimentals
Microdialysis experiments in conscious rats.
-> Treatment and drugs
Male Sprague-Dawley rats, initially weighing 250 - 300 g, were used The animals weie housed under a 12-hr hght/daik cycle under controlled conditions for regulai m-dooi temperatuie (21±2°C) and humidity (55±5%) with food and tap water available ad 0 libitum For tieatments with osmotic mini pumps Alzet, 2ML2 and 2ML4 (Alza Corporation, Palo Alto, USA) were used The pumps were filled under aseptic conditions and implanted subcutanously under Sevorane anaesthesia (Abbott Laboratories, Chicago, USA) Single injections:
Paroxetme and irindalone were injected alone or contemporary in doses of 5 mg/kg and 1 mg/kg s.c, respectively. Combined treatment with paroxetme and irindalone on extracellular 5-HT after acute [2 days] and chronic [14 days] treatments with mmi pumps:
Groups
1 Vehicle, 2 days 2 Paroxetme (10 mg/kg/day), 2 days
3 Paroxetme (10 mg/kg/day) + irindalone (5 mg/kg/day), 2 days
4 Vehicle, 14 days
5. Paroxetme (10 mg/kg/day), 14 days
6 Paroxetme (10 mg/kg/day) + irindalone (5 mg/kg/day), 14 days
Surgery and microdialysis expenments
Surgery was performed as previously described (Mørk, Eur Neuropsvchopharmacol 1998, 8, p 267-272) In brief, animals were anaesthetised with hypnorm/ dormicum (2 ml/kg) and intracerebral guide cannulas (CM A/12) were stereotaxically implanted into the hippocampus, positioning the dialysis probe tip in the ventral hippocampus (co-ordinates 5 6 mm posterior to bregma, lateral -4 8 mm, 4 0 mm ventral to dura) (Paxinos and Watson, 1986, The Rat Brain in Stereotaxic Coordinates, Academic Press, Inc , San Diego, USA) The rats were allowed to recover from surgery for at least 2 days, housed singly in cages
On the day of the expeπment, a microdialysis probe (CMA/12. 0 5 mm diameter, 3 mm length) was inserted through the guide cannula Perfusion of the microdialysis probe with filtered Ringer solution (145 mM NaCl, 3 mM KC1, 1 mM MgCl2, 1 2 mM CaCl2) was begun shortly before insertion of the probe into the bram and continued for the duration of the expeπment at constant flow of 1 μl/mm After the expenments, the rats were sacπficed by decapitation, their brains frozen and sliced (20 μm) and the position of the probes was verified Analysis of dialysate 5-HT
Concentration of 5-HT in the cortical dialysates was analysed by means of HPLC with electrochemical detection. Indoles were separated by reverse phase liquid chromatography (ODS 150 x 3 mm, 3 μm) using a mobile phase consisting of 50 mM NaH2PO4, 40 mg/1 EDTA, 90 mg sodium octanesulfonic acid, and 9% acetonitrile (pH 3.5) at a flow rate of 0.5 ml/min. Electrochemical detection was accomplished using a coulometric detector; potential set at 220 mV (Coulochem II, ESA).
Results:
A single injection of paroxetine increased extracellular 5-HT in the ventral hippocampus by 200% (preinjection levels normalised to 100%). Injection of irindalone contemporarily with paroxetine significantly increased the effect of paroxetine (300%) (preinjection levels normalised to 100%) (P < 0.05). Irindalone alone did not affect the extracellular level of 5-HT.
After 2 days of treatment, extracellular 5-HT was significantly increased in the ventral hippocampus (295%) in animals treated with the combination of paroxetine and irindalone, compared to levels in vehicle animals (normalised to 100%) and animals treated with paroxetine alone (138%)(P < 0.05, group 3 vs groupl and 2- no significant difference between group 1 and 2.
Paroxetine treatment for 14 days significantly increased extracellular 5-HT levels compared to the vehicle treatment (P< 0.05, group 5 vs group 4). However, after 14 days of combined treatment with paroxetine and irindalone, extracellular 5-HT was significantly higher than that observed in the paroxetine group (P< 0.05, group 6 vs group 5).
After 14 days of treatment with paroxetine alone a challenge dose of irindalone (1 mg/kg s.c.) significantly increased the extracellular 5-HT level (270%); prechallenge 5-HT levels normalised to 100% (P < 0,001). Irindalone exerted no effect in vehicle animals. Both citalopram and paroxetine have been demonstrated to increase baseline levels of extracellular 5-HT after 14 days of treatment The effect of the combination of paroxetine and irindalone is observed after 2 days of treatment. These results show that the combination of paroxetine and irindalone provides a fast onset of action and that the potentiating effect of irindalone on paroxetine-mduced increase m extracellular 5-HT is persistent following chronic administration
Thus a better efficacy may be obtained by combined treatment with SRI and irindalone (add-on potential)
Schedule-induced polydipsia
Background
In the schedule-induced polydipsia paradigm, food restricted rats are trained to take a food reward in an operant test chamber, the food reward is delivered on a fixed schedule and the rats exhibit displacement, or stress control, strategies between the delivery of the food pellets In the present model the animals have free access to water and the rats drmk significantly more than would be expected in a normal animal during the time allowed foi the test The anti-stress effects of chronic administration of serotonin reuptake inhibitors has be demonstrated fluoxetme, clomipramme and fluvoxamme have each been demonstrated to reduce schedule-induced water intake, their effects are only observed following chronic administration (1-3 weeks, Woods et al Psvchopharmacolog\ 1993, 772,195-198,) Further, the onset of action of action of the SSRI fluoxetme has been demonstrated to be accelerated by the 5-HT]A and 5-HTI B receptor antagonists, WAY 100,635 and GR 127935, respectively (Hogg and Aπ t Society for Neuroscience 2000, vol 26, abstract No 721 16)
Materials and methods
Rats (male, wistar WU from Møllegard, Denmark) were maintained on a food restricted diet and maintained at 85-90% of their free feeding weight for at least 7 days prior to the start of testing. Animals were trained (4-5 times per week) in an operant chamber on a fixed schedule (1 pellet every 30s) for 30 minutes per session. Drinking water was freely available, water intake was measured for every trial session Following three weeks of training water intake was stable (approximately 12 mL/rat/30 mm) and the animals were randomly allocated to treatment groups
In the present experiment animals were tested on the first day with vehicle administration (all animals) and on days 2 and 3 of testing with one of the following treatments
1 vehicle (paroxetine) + vehicle (irindalone)
2 vehicle (paroxetine) + 5 mg/kg irindalone
3 20 mg/kg paroxetine + vehicle (irindalone)
4 20 mg/kg paroxetine + 5 mg/kg irindalone
All treatments were p o. 60 nun prior to the start of the test sessions Water intake was calculated as % baseline (pretreatment) levels.
Results: The vehicle treatments given on the first test day did not affect water intake.
Treatment with vehicle, paroxetine or irindalone alone did not significantly affect the intake of water relative to baseline or vehicle treated animals, irindalone reduced intake be approximately 8% and paroxetine by appr 12% relative to day one The combination of paroxetine and irindalone reduced water intake A significant effect was observed after the first administration of the compounds whereby the watei consumption was reduced to 50% of baseline levels (P<0 05 vs vehicle treated controls, paroxetine and irindalone alone)
The SRIs fluvoxamme, clomipramme and fluoxetme have all been demonstrated to reduce the intake of water the schedule induce polydipsia model. The onset of action of the SSRIs alone is seen after 1-3 weeks, mirroring the clinical situation The effect of the combination of paroxetine and irindalone is observed after one day's treatment suggesting that this combination would have a fast onset of effect in the clinic
Light/dark box model in the mouse
Materials and methods
Adult male NMRI mice were obtained from Møllegard and housed m group cages (10 pei cage) on a reversed light cycle (12 hour cycle, lights on 18 00) for 3 weeks prior to testing or the start of treatment The two-compartment test box is described by Sanchez et al Pharmacology & Toxicology 1995, 77, 71-78 The test box is open-topped and divided into one black and one white compartment (ratio 2 3) by a partition which is black on the side facing the black compartment and white on the side facing the white compartment The white chamber is made of white perspex except for the lowest 7 5 cm This part is made of transparent perspex (outer walls) and black perspex (partition) The floor of the white compartment is divided into 9 fields and the compartment is illuminated by means of a Schott KL 1500 electronic lamp emitting cold light (560 Lux) The black box is made of black perspex and the floor of this compartment is divided into 6 fields The opening m the partition between the two compartments measures 7,5 x 7,5 cm The test system was fully automated by two rows of 1 1 infrared light sources and photocells in the transverse direction and one row of 16 photocells in the transverse direction (lower row) The lower row of photocells (2 cm above cage flooi ) detects horizontal activity (crossing, entries and time in each compartment), whereas the uppei row of photocells (5 cm above cage floor) detects rearing activity
The black and white boxes aie placed in a dark room The mice were transported to the animal holding room adjacent to the test room 18 hours before the test The test was performed as follows the mouse was placed into the centie of the bπghtly- lit white compartment facing the opening to the black compartment and allowed to freely explore the apparatus for a total of 5 mm The light beams weie used to assess activity around the test box and critically the time for which the animals exploied the light and daik sections thereof
Treatment
Acute interaction experiments
Animals were randomly assigned to the following groups (8 mice per group)
1 vehicle (paroxetme) + vehicle (irindalone)
2 paroxetme (5 mg/kg) + vehicle (irindalone) 3 paroxetine (vehicle) + irindalone (0 31 mg/kg)
4 paroxetine (vehicle) + irindalone (1 3 mg/kg)
5 paroxetme (5 mg/kg) + irindalone (0.31 mg/kg)
6 paroxetine (5 mg/kg) + irindalone (1.3 mg/kg) Treatments were given sub cutaneous ly 30 min prior to testing.
Result - acute interaction:
Animals in group 1 spent an average of 127 s (from a maximum of 300 s) in the light section of the box. Treatment with paroxetine (group 2) increased this to 143 s which is not significant. Animals treated with irindalone alone (groups 3 and 4) had average times in light of 140 and 148 s for 0.31 and 1.3 mg/kg doses, respectively; which is not significant. The mice treated with the combination of paroxetine and irindalone spent an average of 162 s (group 5) and 174 s (group 6) in the light. Group 5 was significantly different from group 1 (P<0.05) whilst group 6 was significantly different from group 1 , group 2 and group 4 (P<0.05).
Thus animals treated with the combination of irindalone and paroxetine appear to be less anxious than those treated with either compound alone. A similar effect has been observed using citalopram as the SSRI of choice.
Treatment: Chronic studies
Animals were treated chronically with an SSRI and acutely with irindalone according to the following schedule:
Figure imgf000019_0001
Results:
Animals treated with the two vehicles had an average time in light of 123 + 16 s. Treatment with paroxetine did not significantly change the level of exploration in light (group 2, 132 + 10 s; group 3, 140 + 12 s; group 4, 157 + 10 s; not significant). Similarly, irindalone alone (group 5) was without effect (average time in light 142 + 20 s; not significant). The animals treated with the combination of paroxetine and irindalone have the following average times in light; group 6, 143 + 1 1 s; group 7, 203 + 22 s (PO.05 vs groups 1 and 3) and group 8, 206 + 10 s (P<0.05 vs groups 1, 4 and 5).
Thus the animals treated with the combination of chronic paroxetine and acute irindalone appeared less anxious than those treated with either compound alone. A similar result has also been obtained using citalopram as the SSRI of choice.
Thus, irindalone potentiated the anxiolytic potential of paroxetine suggesting better efficacy for the combination treatment than the paroxetine alone. The benefit was observed following acute and importantly chronic treatment with paroxetine suggesting the potential of irindalone as an "add-on" therapy to enhance the efficacy of SSRIs.

Claims

Claims:
1 The use of irindalone or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition to be used m combination with a serotonin reuptake inhibitor inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin
2 The use of irindalone or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition useful for augmenting and/or providing faster onset of the therapeutic effect of a serotonin leuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin
3 The use according to claims 1 or 2 wherein the serotonin reuptake inhibitor or the compound, which causes an elevation in the level of extracellular serotonin, is used in the treatment of depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder and drug abuse
4 The use according to claim 3 wherein the serotonin reuptake inhibitor or the compound, which causes an elevation in the level of extracellular serotonin, is used in the tieatment of anxiety disorders including general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disordei
5 The use according to claim 3 wherein the serotonin reuptake inhibitor or the compound, which causes an elevation in the level of extracellular serotonin, is used in the treatment of depression
6 The use according to claims 1 to 5 wherein the tartrate salt of irindalone is used
7 The use according to claims 1 to 6 wherein the serotonin reuptake inhibitor is selected from citalopram, escitalopram, fluoxetme, sertralme, paroxetine, fluvoxamme, venlafaxine, dapoxetme, nefazodone, lmipramin, femoxetme and clomipramme or a pharmaceutically acceptable salt of any of these compounds
8 The use according to claim 7 wherein the serotonin reuptake inhibitor is a selective serotonin reuptake inhibitor
9 The use according to claim 8 wherein the serotonin reuptake inhibitor is selected from citalopram, escitalopram, fluoxetme, fluvoxamme, sertralme and paroxetine or a pharmaceutically acceptable salt of any of these compounds
10 The use of irindalone or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin , for the preparation of a pharmaceutical composition oi kit for the treatment of diseases or disorders responsive to the therapeutic effect of a serotonin reuptake inhibitor or any other compound causing an elevation in the level of extracellular serotonin
1 1 The use according to claim 10 for the preparation of a pharmaceutical composition oi kit useful for the treatment of depression, anxiety disordeis and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse contiol disorders, attention deficit hyperactivity disorder and drug abuse
12 The use according to claim 1 1 for the preparation of a phaπnaceutical composition or kit useful for the treatment of anxiety disorders, including general anxiety disordei, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder
13 The use according to claim 1 1 for the preparation of a pharmaceutical composition for the treatment of depression
14. The use according to claims 10 to 13 wherein irindalone is used in the form of a tartrate salt.
15. The use according to claims 10 to 14 wherein the serotonin uptake inhibitor is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, nefazodone, imipramin, femoxetine and clomipramine or a pharmaceutically acceptable salt of any of these compounds.
16. The use according to claim 15 wherein the serotonin reuptake inhibitor used is a selective serotonin reuptake inhibitor.
17. The use according to claim 16 wherein the selective serotonin reuptake inhibitor is citalopram, escitalopram, fluoxetine, fluvoxamine, sertraline and paroxetine or a pharmaceutically acceptable salt of any of these compounds.
18. The use according to claims 10-17 wherein the pharmaceutical composition prepared is adapted for simultaneous administration of the active ingredients.
19. The use according to claim 18 wherein the active ingredients are contained in the same unit dosage form.
20. The use according to claims 10-17 wherein the pharmaceutical composition prepared is adapted for sequential administration of the active ingredients.
21. The use according to claim 20 wherein the active ingredients are contained in discrete unit dosage forms.
22. A pharmaceutical composition or kit comprising irindalone or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, and optionally pharmaceutically acceptable carriers or diluents.
23. A pharmaceutical composition or kit according to claim 22 containing irindalone in the form of the tartrate salt thereof.
24. The pharmaceutical composition or kit according to claims 22 to 23 characterised in that the serotonin uptake inhibitor is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, nefazodone, imipramin, femoxetine and clomipramine or a pharmaceutically acceptable salt of any of these compounds.
25. The pharmaceutical composition or kit according to claim 24 wherein the serotonin reuptake inhibitor is a selective serotonin reuptake inhibitor.
26. The pharmaceutical composition or kit according to claim 25 wherein the selective serotonin reuptake inhibitor is citalopram, escitalopram, fluoxetine, fluvoxamine, sertraline and paroxetine or a pharmaceutically acceptable salt of any of these compounds.
27. The pharmaceutical composition according to claims 22 to 26 which is adapted for simultaneous administration of the active ingredients.
28. The pharmaceutical composition according to claim 27 wherein the active ingredients are contained in the same unit dosage form.
29. The pharmaceutical composition or kit according to claims 22 to 26 which is adapted for sequential administration of the active ingredients.
30. The pharmaceutical composition according to claim 29 wherein the active ingredients are contained in discrete dosage forms.
31. A method for the treatment of diseases or disorders responsive to a serotonin reuptake inhibitor or any other compound which causes an elevation in the level of extracellular serotonin, comprising administering irindalone or a pharmaceutically acceptable salt thereof and a serotonin reuptake inhibitor, or a compound which causes an elevation in the level extracellular serotonin, to an individual in need thereof.
32. A method for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, comprising administering irindalone or a pharmaceutically acceptable salt thereof to an individual to be treated with or undergoing treatment with the serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin.
33. A method according to claims 31 to 32 wherein the individual suffers from depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder and drug abuse.
34. The method according to claim 33 wherein the individual suffers from anxiety disorder, including general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder.
35. The method according to claim 33 wherein the individual suffers from depression.
36. The method according to claims 31 to 32 wherein irindalone is used in the form of the tartrate salt.
37. The method according to claims 31 to 32 wherein the serotonin uptake inhibitor is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, nefazodone, imipramin, femoxetine and clomipramine or a pharmaceutically acceptable salt of any of these compounds.
38. The method according to claim 37 wherein the serotonin reuptake inhibitor is a selective serotonin reuptake inhibitor.
39. The pharmaceutical composition according to claim 38 wherein the selective serotonin reuptake inhibitor is citalopram, escitalopram, fluoxetine, fluvoxamine, sertraline and paroxetine or a pharmaceutically acceptable salt of any of these compounds.
40. The method according to claims 31-39 wherein the active ingredients are administered simultaneously.
41. The method according to claim 40 wherein the active ingredients are administered in the same unit dosage from.
42. The method according to claims 31-39 wherein the active ingredients are administered sequentially.
43. The method according to claim 42 wherein the active ingredients are contained in two discrete unit dosage forms.
PCT/DK2000/000667 1999-12-06 2000-12-04 The combination of a serotonin reuptake inhibitor and irindalone WO2001041766A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU18508/01A AU1850801A (en) 1999-12-06 2000-12-04 The combination of a serotonin reuptake inhibitor and irindalone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16924599P 1999-12-06 1999-12-06
US60/169,245 1999-12-06

Publications (1)

Publication Number Publication Date
WO2001041766A1 true WO2001041766A1 (en) 2001-06-14

Family

ID=22614803

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/DK2000/000667 WO2001041766A1 (en) 1999-12-06 2000-12-04 The combination of a serotonin reuptake inhibitor and irindalone
PCT/DK2000/000671 WO2001041701A2 (en) 1999-12-06 2000-12-06 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/DK2000/000671 WO2001041701A2 (en) 1999-12-06 2000-12-06 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist

Country Status (33)

Country Link
US (4) US20020103249A1 (en)
EP (2) EP2036564A1 (en)
JP (1) JP2003516326A (en)
KR (1) KR100832026B1 (en)
CN (2) CN1433313A (en)
AT (1) ATE314849T1 (en)
AU (2) AU1850801A (en)
BG (1) BG106895A (en)
BR (1) BR0016385A (en)
CA (1) CA2393470A1 (en)
CO (1) CO5251409A1 (en)
CY (1) CY1105014T1 (en)
CZ (1) CZ20021961A3 (en)
DE (1) DE60025398T2 (en)
DK (1) DK1237553T3 (en)
EA (1) EA006391B1 (en)
ES (1) ES2255519T3 (en)
HR (1) HRP20020527A2 (en)
HU (1) HUP0203586A3 (en)
IL (2) IL149994A0 (en)
IS (1) IS2227B (en)
ME (1) MEP6208A (en)
MX (1) MXPA02005613A (en)
NO (1) NO20022657L (en)
NZ (1) NZ545907A (en)
PL (1) PL356402A1 (en)
PT (1) PT1237553E (en)
SK (1) SK7962002A3 (en)
TR (1) TR200201512T2 (en)
UA (1) UA77650C2 (en)
WO (2) WO2001041766A1 (en)
YU (1) YU41902A (en)
ZA (1) ZA200204391B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008013556A1 (en) 2006-07-27 2008-01-31 Janssen Pharmaceutical N.V. Combination 5-ht7 receptor antagonist and serotonin reuptake inhibitor therapy
WO2009082268A2 (en) 2007-12-21 2009-07-02 Alla Chem, Llc LIGANDS OF α-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF
US8618288B2 (en) 2003-09-17 2013-12-31 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (en) * 1999-07-08 2002-06-12 Lundbeck & Co As H TREATMENT OF NEUROTIC DISORDERS
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
US6589996B2 (en) 2000-03-17 2003-07-08 Orion Corporation Treatment of disorders relating to the serotonergic system
WO2002043727A1 (en) * 2000-11-28 2002-06-06 Orion Corporation Treatment of psychiatric disorders with trimethyl-bicyclo[2.2.1]heptane derivatives
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
FI20002612A0 (en) * 2000-11-28 2000-11-28 Orion Yhtymae Oyj Combination therapy for the treatment of disorders in serotonin turnover
US6335372B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Treatment of obsessive compulsive disorder
EA200301195A1 (en) * 2001-05-01 2004-04-29 Х. Лундбекк А/С APPLICATION OF ENANTIOMERALLY CLEAN ESCYTAL PREMA
GB0118892D0 (en) * 2001-08-02 2001-09-26 Vernalis Res Ltd Method of treatment
SE0201544D0 (en) * 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
WO2005000216A2 (en) * 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR047553A1 (en) * 2003-07-04 2006-01-25 Lundbeck & Co As H THE COMBINATION OF A SEROTONINE AND AGOMELATINE REABSORTION INHIBITOR
EP1500391A1 (en) * 2003-07-24 2005-01-26 Neuro3D Therapeutic use of bicycloheptane derivatives
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James Combination therapy for dementia,depression and apathy
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050241110A1 (en) * 2004-04-09 2005-11-03 Bruce Baker Ergonomic handles, especially for garden tools
WO2007107165A1 (en) * 2006-03-22 2007-09-27 H. Lundbeck A/S Method for identifying compounds for the treatment of depression
WO2007144005A1 (en) 2006-06-16 2007-12-21 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
EP2185155B1 (en) * 2007-08-03 2017-10-04 Richter Gedeon Nyrt. Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
CA2730385A1 (en) * 2008-07-10 2010-01-14 Ore Pharmaceuticals Inc. Treating inflammation and related conditions with irindalone
JP5722891B2 (en) 2010-07-15 2015-05-27 大日本住友製薬株式会社 Pyrazole compounds
EP2629615B1 (en) 2010-10-22 2018-10-10 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
WO2014046544A1 (en) 2012-09-21 2014-03-27 Aapa B.V. Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
WO2016205631A1 (en) * 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders
CN107556206A (en) * 2016-06-30 2018-01-09 陕西合成药业股份有限公司 A kind of new 5 serotonin reuptake inhibitor class compound and preparation method thereof and application medically
US11478467B2 (en) 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0684237A1 (en) * 1993-02-10 1995-11-29 Yamanouchi Pharmaceutical Co. Ltd. Morpholine derivative
GB2303303A (en) * 1995-07-13 1997-02-19 American Home Prod 5HT-1A and 5HT-2 antagonists for treating side-effects of serotonin re-uptake inhibitors
WO1999061027A1 (en) * 1998-05-22 1999-12-02 Eli Lilly And Company Combination therapy for treatment of refractory depression
EP0966967A2 (en) * 1998-05-29 1999-12-29 Eli Lilly And Company Combination therapy of olanzapine (zyprexa) and fluoxetine (prozac) for treatment of bipolar disorder

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5155218A (en) * 1990-05-08 1992-10-13 Neurogenetic Corporation Dna encoding human 5-ht1d receptors
AU4704693A (en) 1992-08-20 1994-03-15 Smithkline Beecham Plc Condensed indole derivatives as 5HT-2C and 5HT-2B antagonists
WO1994014801A1 (en) 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
GB9313913D0 (en) 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
MX9700693A (en) * 1994-07-26 1997-04-30 Pfizer 4-indole derivatives as serotonin agonists and antagonists.
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug response by a serotonin 1A receptor antagonist
EP0807104A2 (en) 1995-02-02 1997-11-19 Smithkline Beecham Plc Heterocyclic compounds possessing 5ht 2c? receptor antagonist activity
SE9501567D0 (en) * 1995-04-27 1995-04-27 Astra Ab A new combination
GB9511355D0 (en) 1995-06-06 1995-08-02 Fujisawa Pharmaceutical Co Urea derivatives
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
FR2744449B1 (en) 1996-02-02 1998-04-24 Pf Medicament NOVEL AROMATIC PIPERAZINES DERIVED FROM SUBSTITUTED CYCLOAZANES, AS WELL AS THEIR PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS MEDICAMENTS
GB9607219D0 (en) 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
EP0892804B1 (en) 1996-04-12 2002-08-28 Janssen Pharmaceutica N.V. Isoxazolidine derivatives
EP0813873B1 (en) 1996-06-19 2002-02-13 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
SE9703375D0 (en) * 1997-09-18 1997-09-18 Astra Ab A new combination
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
DE19827750C1 (en) * 1998-06-22 1999-07-29 Centeon Pharma Gmbh Separating human immunodeficiency virus from fluid, useful for lowering HIV virus load in extracorporeal blood
DE19900673A1 (en) * 1999-01-11 2000-07-13 Basf Ag Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0684237A1 (en) * 1993-02-10 1995-11-29 Yamanouchi Pharmaceutical Co. Ltd. Morpholine derivative
GB2303303A (en) * 1995-07-13 1997-02-19 American Home Prod 5HT-1A and 5HT-2 antagonists for treating side-effects of serotonin re-uptake inhibitors
WO1999061027A1 (en) * 1998-05-22 1999-12-02 Eli Lilly And Company Combination therapy for treatment of refractory depression
EP0966967A2 (en) * 1998-05-29 1999-12-29 Eli Lilly And Company Combination therapy of olanzapine (zyprexa) and fluoxetine (prozac) for treatment of bipolar disorder

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8618288B2 (en) 2003-09-17 2013-12-31 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US8883808B2 (en) 2005-08-04 2014-11-11 Janssen Pharmaceutica N.V. Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy
WO2008013556A1 (en) 2006-07-27 2008-01-31 Janssen Pharmaceutical N.V. Combination 5-ht7 receptor antagonist and serotonin reuptake inhibitor therapy
WO2009082268A2 (en) 2007-12-21 2009-07-02 Alla Chem, Llc LIGANDS OF α-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF

Also Published As

Publication number Publication date
ATE314849T1 (en) 2006-02-15
KR100832026B1 (en) 2008-05-23
CA2393470A1 (en) 2001-06-14
US20020103249A1 (en) 2002-08-01
EP1237553A2 (en) 2002-09-11
AU1851101A (en) 2001-06-18
ZA200204391B (en) 2003-11-26
IS2227B (en) 2007-04-15
WO2001041701A3 (en) 2001-12-13
IL149994A (en) 2007-07-24
EA006391B1 (en) 2005-12-29
PT1237553E (en) 2006-05-31
PL356402A1 (en) 2004-06-28
BR0016385A (en) 2003-02-18
NO20022657L (en) 2002-07-26
CY1105014T1 (en) 2009-11-04
SK7962002A3 (en) 2002-09-10
HUP0203586A2 (en) 2003-03-28
EP2036564A1 (en) 2009-03-18
IS6404A (en) 2002-05-31
CN1433313A (en) 2003-07-30
WO2001041701A2 (en) 2001-06-14
CZ20021961A3 (en) 2002-11-13
US20090176808A1 (en) 2009-07-09
KR20020060987A (en) 2002-07-19
TR200201512T2 (en) 2002-09-23
HUP0203586A3 (en) 2005-02-28
DK1237553T3 (en) 2006-05-15
US20030032636A1 (en) 2003-02-13
DE60025398D1 (en) 2006-03-30
US20070105843A1 (en) 2007-05-10
HRP20020527A2 (en) 2004-12-31
DE60025398T2 (en) 2006-08-03
CN101406465A (en) 2009-04-15
ES2255519T3 (en) 2006-07-01
IL149994A0 (en) 2002-12-01
BG106895A (en) 2003-04-30
MEP6208A (en) 2010-02-10
NO20022657D0 (en) 2002-06-05
CO5251409A1 (en) 2003-02-28
MXPA02005613A (en) 2002-12-13
UA77650C2 (en) 2007-01-15
EP1237553B1 (en) 2006-01-04
AU1850801A (en) 2001-06-18
NZ545907A (en) 2007-07-27
EA200200649A1 (en) 2002-12-26
JP2003516326A (en) 2003-05-13
YU41902A (en) 2005-06-10

Similar Documents

Publication Publication Date Title
WO2001041766A1 (en) The combination of a serotonin reuptake inhibitor and irindalone
Nguyen et al. Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
US20100267772A1 (en) Combination of a Serotonin Reuptake Inhibitor and Agomelatine
US20090203731A1 (en) Treatment of depression and other affective disorders
US20070010543A1 (en) Compositions and methods for treating gastrointestinal hypomotility and associated disorders
US20110034565A1 (en) Psycho-pharmaceuticals
EP2145620A2 (en) Gaboxadol for treating depression and other affective disorders
US20120258984A1 (en) 5-htp combination therapy
US20070117844A1 (en) 5-HTP combination therapy
WO2008035177A2 (en) Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor
Kivastik Mechanisms of drug addiction: focus on positive reinforcing properties of morphine
WO2005023243A1 (en) The combination of a serotonin reuptake inhibitor and loxapine
US20070042014A1 (en) Combination of a serotonin reuptake inhibitor and loxapine
Guglielmo et al. Topiramate, Naltrexone, and Acamprosate in the Treatment of Alcohol Use Disorders
ZA200509588B (en) The combination of a serotonin reuptake inhibitors and agomelatine
US20080167290A1 (en) Combination of a Serotonin Reuptake Inhibitor and Amoxapine
AU2007353453A1 (en) 5-HTP combination therapy
CA2537757A1 (en) The combination of a serotonin reuptake inhibitor and amoxapine
MX2008016138A (en) 5-htp combination therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP